News | Heart Failure | July 18, 2023

Quidel Cardiovascular Inc. Recalls Quidel Triage Cardiac Panels for Risk of False Negative Troponin Results

Quidel Cardiovascular is recalling its Quidel Triage Cardiac Panels for risk of false negative troponin results that could cause delayed diagnosis or missed myocardial infarction

Quidel Cardiovascular is recalling its Quidel Triage Cardiac Panels for risk of false negative troponin results that could cause delayed diagnosis or missed myocardial infarction

July 18, 2023 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall on Quidel Cardiovascular is recalling its Quidel Triage Cardiac Panels for risk of false negative troponin results that could cause delayed diagnosis or missed myocardial infarction. 

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries, serious health consequences, or death. 


Recalled Product 

Product Names: 

  • Quidel Triage Cardiac Panel 
  • Quidel Triage Cardiac Panel, Troponin I 
  • Quidel Triage Cardiac Panel, CK-MB and Troponin I 

Product Codes: 

  • 97000HS 
  • 97021HS 
  • 97022HS 

Product Lots: See Medical Device Recall Database entry 

Distribution Dates: Beginning November 1, 2022 

Devices Recalled in the U.S.: 7,799 

Date Initiated by Firm: May 25, 2023 


Device Use 

The Quidel Triage Cardiac Panel is a blood test that detects amounts of specific enzymes (creatine kinase MB or CK-MB) and proteins (myoglobin and troponin I) in blood or plasma samples. The test is used to help doctors quickly diagnose when someone is experiencing a heart attack (myocardial infarction) and other life-threatening injuries to the heart muscle. 


Reason for Recall 

Quidel Cardiovascular Inc. (QuidelOrtho) is recalling the Quidel Triage Cardiac Panel after reports of inaccurate tests showing lower than expected troponin levels in samples. 

A falsely low or false negative troponin level may cause a delayed or missed diagnosis of myocardial infarction — a serious, potentially fatal condition that requires the earliest detection possible to treat and protect the heart muscle effectively. This poses a particular risk to people who experience a silent myocardial infarction with no other symptoms, those who have unusual or atypical symptoms, and those with non-ST-segment elevation myocardial infarction (NSTEMI). 

Continued use of these products without appropriate mitigations could cause serious injury or death. 

QuidelOrtho reports 41 complaints, no injuries, and no deaths related to this issue. 


Who May be Affected 

  • People who have suspected myocardial infarction whose troponin levels are tested using the Quidel Cardiac Triage Panel. 
  • Health care personnel assessing patients for possible myocardial infarction using the Quidel Cardiac Triage Panel. 


What to Do 

On May 25, 2023, QuidelOrtho sent an Urgent Product Correction Notification and on July 12, 2023 sent an updated Notification to Customers. These letters included the following recommended actions for customers and users: 

Immediately discontinue use of this product and use an alternate method, or send patients to another local testing site utilizing an alternate method. If an alternate method or alternate local testing site is not available, see Required Actions for recommendations on how to mitigate potential patient impact when continuing use of the product. 


Required Actions for Customers Using Impacted Product Lots 

  • If you have an alternate method, or another local testing site using an alternative method is available for testing, please throw away all unused Quidel test kits. 
  • If you do not have an alternate method, or another local testing site with an alternative method is not available, please follow these steps, as applicable, to minimize patient risk. 
    • Flag ALL negative results reported to clinicians as possibly inaccurate until lots of unaffected product are available. 
    • Use results from an alternate clinical laboratory analyzer or alternate testing site when troponin results are below or close to the cutoff and myocardial infarction is suspected. 
    • Perform serial sampling. Keep patients until at least three negative troponin values have been obtained. 
    • Use all Triage troponin results in conjunction with the patient’s risk factors, clinical presentation, EKG, and other imaging. 
    • Consider recommendations by the American College of Cardiology, guidelines from the European Society of Cardiology, and the Fourth Universal Definition of Myocardial Infarction for monitoring a patient for a rise or fall pattern of troponin. 
    • If you are experiencing issues with Proficiency testing, contact your local Technical Solutions Center. 
  • Forward this notification if the product was distributed outside of your facility. 


Contact Information 

Customers with questions should contact QuidelOrtho at 858-552-1100 or contact the local QuidelOrtho Technical Solutions Center. 

Additional Resources 

Medical Device Recall Database entry 

How do I report a problem? 

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using an online form, regular mail, or FAX.

Related Content

Feature | Cardiac Diagnostics | By Robert L. Quigley, MD, DPhil

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes ...

Home January 23, 2024
News | Cardiac Diagnostics

September 5, 2023 — GE HealthCare announced the launch of a handheld, wireless ultrasound imaging system designed for ...

Home September 05, 2023
Feature | Cardiac Diagnostics | By Kelly Patrick

The global ambulatory diagnostic cardiology market was valued at $2.6 billion in 2022 and is forecast to rise to $3.3 ...

Home May 15, 2023
News | Cardiac Diagnostics

February 8, 2023 — Results of research that identified new causes of Atherosclerotic Coronary Artery Disease, or ASCAD ...

Home February 08, 2023
News | Cardiac Diagnostics

September 15, 2022 - Happitech has announced the launch of its FastStart Research app. The Amsterdam-based digital ...

Home September 15, 2022
Feature | Cardiac Diagnostics | by Kelly Patrick

Like most healthcare markets, the diagnostic cardiology market has had a bumpy ride in recent years. The COVID-19 ...

Home August 23, 2022
Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Feature | Cardiac Diagnostics | By Dave Fornell, DAIC Editor

October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides ...

Home October 29, 2021
Subscribe Now